Difference between revisions of "Disclosure statement (from DOI: 10.1080/22221751.2020.1735265) (Q8419)"
Jump to navigation
Jump to search
(Created claim: Has Sectioning (P146): Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265) (Q8415), #quickstatements; #temporary_batch_1589488703697) |
(Created claim: Has Sectioning (P146): Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8416), #quickstatements; #temporary_batch_1589488703697) |
||
| Property / Has Sectioning | |||
| + | |||
| Property / Has Sectioning: Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265) / rank | |||
| + | Normal rank | ||
Revision as of 20:52, 14 May 2020
Publication: "Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection" in the journal Emerg Microbes Infect (2020); DOI: 10.1080/22221751.2020.1735265
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Disclosure statement (from DOI: 10.1080/22221751.2020.1735265)
|
Publication: "Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection" in the journal Emerg Microbes Infect (2020); DOI: 10.1080/22221751.2020.1735265
|
Statements
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
